Krishnamurthy, Sateesh
Wohlford-Lenane, Christine
Kandimalla, Suhas
Sartre, Gilles
Meyerholz, David K. http://orcid.org/0000-0003-1552-3253
Théberge, Vanessa
Hallée, Stéphanie
Duperré, Anne-Marie
Del’Guidice, Thomas http://orcid.org/0000-0003-4969-7016
Lepetit-Stoffaes, Jean-Pascal
Barbeau, Xavier
Guay, David
McCray, Paul B. Jr. http://orcid.org/0000-0002-4067-577X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (1UG3 HL-147366-01, P01 HL-51670, P01 HL-091842)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK-54759)
Cystic Fibrosis Foundation (MCCRAY15XX0)
Roy J. Carver Charitable Trust
Article History
Received: 4 June 2019
Accepted: 30 September 2019
First Online: 28 October 2019
Competing interests
: P.B.M. is a founder of and holds equity in Talee Bio. D.G. holds equity in Feldan Therapeutics. D.G., T.D., and J.-P.L.-S. hold employee stock options from Feldan Therapeutics. V.T., S.H., A.-M.D., T.D., J.-P.L.-S., X.B., and D.G. are employees of Feldan Therapeutics. D.G., T.D., and J.-P.L.-S. are inventors of US Patents No. 9,738,687 and 9,982,267 related to this technology and assigned to Feldan Bio Inc. The other authors declare no competing interests.